Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stock Position Lowered by Perceptive Advisors LLC

Perceptive Advisors LLC lessened its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 5.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,917,634 shares of the company’s stock after selling 183,268 shares during the quarter. Centessa Pharmaceuticals makes up about 1.3% of Perceptive Advisors LLC’s holdings, making the stock its 24th biggest holding. Perceptive Advisors LLC’s holdings in Centessa Pharmaceuticals were worth $72,970,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in CNTA. Avoro Capital Advisors LLC lifted its position in shares of Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares in the last quarter. EcoR1 Capital LLC lifted its position in shares of Centessa Pharmaceuticals by 466.4% in the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after acquiring an additional 2,565,000 shares in the last quarter. Braidwell LP purchased a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $54,730,000. Maverick Capital Ltd. purchased a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $41,110,000. Finally, Adage Capital Partners GP L.L.C. lifted its position in shares of Centessa Pharmaceuticals by 20.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after acquiring an additional 1,449,000 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CNTA. Leerink Partners downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their price target for the company from $36.00 to $40.00 in a research report on Wednesday, April 1st. Lifesci Capital downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Needham & Company LLC downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Finally, Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a research report on Monday, April 13th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Stock Up 0.3%

CNTA stock opened at $39.87 on Thursday. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $12.30 and a 12-month high of $40.26. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The company has a market cap of $6.17 billion, a price-to-earnings ratio of -22.27 and a beta of 1.11. The company has a 50 day moving average of $39.65 and a two-hundred day moving average of $31.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 41,076 shares of the firm’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This trade represents a 39.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.